

# Siegfried Engages New Chief Scientific Officer



Siegfried Group (SFZN) announces a change in corporate management. Jürgen Roos, Ph.D., was appointed the company's new Chief Scientific Officer. Roos will join Siegfried's Executive Committee and take on responsibility for Research and Development with effect from 1 April 2019. In this function he will succeed Wolfgang Wienand, Ph.D., who was appointed Chief Executive Officer with effect from 1 January 2019 and will continue to manage Siegfried's Strategy and M&A Department. Jürgen Roos has been employed by Evonik Industries AG for many years and held several Management positions in Research, Development and Innovation, most recently as Vice President Innovation Management of the Nutrition & Care Business Unit.

Wolfgang Wienand, Chief Scientific and Strategy Officer and designated CEO: «Jürgen Roos is a proven professional. He is ideally suited to head our global Research and Development activities. In addition to profound scientific knowledge, Jürgen Roos enjoys wide experience in the Management of large R&D organizations and has intimate knowledge of the pharmaceutical business».

---

## Contact

Peter A. Gehler  
Chief Communications Officer  
peter.gehler@siegfried.ch  
Tel. +41 62 746 11 48  
Mobile +41 79 416 41 16

Siegfried Holding AG  
Untere Bruehlstrasse 4  
CH-4800 Zofingen

---

## This Media Release on the web

[www.siegfried.ch/media-releases](http://www.siegfried.ch/media-releases)

---

## About Siegfried

The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2017, Siegfried reported annual sales of CHF 751 million and employs at the time being approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.

---

## Appendix

### **CV Dr. Jürgen Roos (1968)**

Jürgen Roos studied chemistry at the University of Stuttgart and subsequently obtained a Ph.D. in organic chemistry. In 1999, he started working as laboratory team leader in chemical research in the field of fine chemicals at Evonik Industries AG (formerly Degussa-Hüls and Degussa AG). Following other professional posts within the R&D organization of Evonik, including several years in Canada and the United Kingdom, he was appointed head of process development in exclusive synthesis in 2008. Subsequently, he took on global responsibility for research and development of the Health Care division. In this function he gathered broad experience in the field of chemical substances and finished dosage forms. Since April 2017, Jürgen Roos has been responsible as Vice President for Innovation Management of the Animal Nutrition business unit.

Jürgen Roos is a German citizen.